ライフサイエンスコーパス: CD4 lymphocyte count

1 nol equivalent (200,000 IU), on HIV load and CD4 lymphocyte count.

2 lated with RNA copy number (P < .01) but not CD4 lymphocyte count.

3 of KSHV/HHV-8 DNA did not correlate with the CD4 lymphocyte count.

4 county, age group, sex, HIV/AIDS status, and CD4 lymphocyte count.

5 rifamycin resistance among patients with low CD4 lymphocyte counts.

6 al reasons may account for BL deficit at low CD4 lymphocyte counts.

7 ith ongoing HIV replication but may increase CD4+ lymphocyte counts.

8 infection and inversely correlates with the CD4(+) lymphocyte count.

9 correlated with lower viral loads and higher CD4(+) lymphocyte counts.

10 gly associated with HIV RNA levels than with CD4(+) lymphocyte counts.

11 red immunodeficiency syndrome (AIDS) (median CD4+ lymphocyte count -21/microl) who participated in a

12 of control subjects (odds ratio adjusted for CD4 lymphocyte count, 3.8; 95% confidence interval, 2.2-

13 f the 494 study participants (median initial CD4(+) lymphocyte count, 518 lymphocytes/mm(3)), 90 (18%

14 The HIV test result was negative, and the CD4 lymphocyte count and complement and immunoglobulin l

15 Risk factors included decreasing CD4 lymphocyte count and history of AIDS-defining illnes

16 Cheaper, simpler alternatives to CD4 lymphocyte count and HIV-1 RNA detection for assessi

17 The relationship between CD4 lymphocyte count and the in vitro effect of interleu

18 ence of both conditions increases with lower CD4 lymphocyte counts and higher HIV-1 RNA levels.

19 n ongoing hepatitis C virus (HCV) infection, CD4 lymphocyte counts and serum concentrations of HCV RN

20 age HIV-1 infection and correlated with both CD4(+) lymphocyte count and HIV-1 RNA level.

21 CD4(+) lymphocyte count and human immunodeficiency virus

22 l, body mass index, and (for those with HIV) CD4+ lymphocyte count and HIV RNA levels.

23 te, these effects remained significant after CD4+ lymphocyte count and plasma HIV-1 RNA load at basel

24 t HIV-1 disease progression independently of CD4+ lymphocyte count and plasma HIV-1 RNA load, suggest

25 ad strongly predicts the rate of decrease in CD4+ lymphocyte count and progression to AIDS and death,

26 ollowed (in order of predictive strength) by CD4+ lymphocyte count and serum neopterin levels, serum

27 th past or current HGV infection have higher CD4+ lymphocyte counts and better AIDS-free survival rat

28 oth men and women, is associated with higher CD4+ lymphocyte counts and lower plasma HIV viral burden

29 CD4+ lymphocyte counts and plasma HIV-1 RNA levels predi

30 by the use of end points such as changes in CD4+ lymphocyte counts and plasma levels of human immuno

31 ral load discriminated risk at all levels of CD4+ lymphocyte counts and predicted their subsequent ra

32 Plasma vitamin A level, CD4 lymphocyte count, and HIV load were measured at base

33 Change in size of the parotid cyst, CD4 lymphocyte count, and HIV viral load.

34 or type II (sTNF alpha RII) levels in serum, CD4 lymphocyte counts, and human immunodeficiency virus

35 ed clinical, demographic, and exposure data, CD4 lymphocyte counts, and stool samples for detection o

36 younger, injection drug use, lower baseline CD4+ lymphocyte count, and higher baseline viral load.

37 ographic variables, plasma HIV-1 RNA levels, CD4+ lymphocyte counts, and adverse drug reactions.

38 reserved plasma samples, previously obtained CD4+ lymphocyte counts, and clinical events.

39 Two key laboratory markers--plasma RNA and CD4+ lymphocyte count-are independent predictors of clin

40 ciated with the magnitude of the increase in CD4 lymphocyte count, as were haplotypes in genes encodi

41 ion had no significant impact on HIV load or CD4 lymphocyte count at 2 and 4 weeks after treatment.

42 Median CD4 lymphocyte count at diagnosis of a new ADI increased

43 ncer, concomitant steroid treatment, and low CD4 lymphocyte count at RTX initiation.

44 he same CD4 count, whereas women have higher CD4 lymphocyte counts at the time of AIDS diagnosis.

45 , a higher weight, and HIV viremia and lower CD4 lymphocyte counts at the time of HAV vaccination wer

46 se at 6 months of HAV vaccination and higher CD4 lymphocyte counts at vaccination were inversely asso

47 The median CD4(+) lymphocyte count at lymphoma diagnosis has decrea

48 The CD4+ lymphocyte count at entry was >500/microL for 6 sub

49 increased with early infection, low maternal CD4+ lymphocyte count at recruitment, and frequent morbi

50 th each of the following: decreased maternal CD4+ lymphocyte counts at base line; decreased maternal

51 After controlling for age, baseline CD4(+) lymphocyte count, baseline HIV-1 RNA level, and d

52 lure or relapse was associated with baseline CD4 lymphocyte count, being 12.3% (9/73; 95% confidence

53 other non-Hodgkin lymphoma (NHL), by age and CD4 lymphocyte count categories, were estimated using Po

54 RNA level plus a 10 percent increase in the CD4+ lymphocyte count could explain 79 percent of the tr

55 22 who were positive for HGV RNA, had higher CD4+ lymphocyte counts (difference, 211 cells/mm3 [95% C

56 Plasma beta 2-microglobulin levels and CD4+ lymphocyte counts explained less of the effect of t

57 medical histories, serum HIV RNA loads, and CD4+ lymphocyte counts for mothers were examined by logi

58 eatment-naive or interferon-experienced, had CD4+ lymphocyte count >/=200 cells/microL or >/=14%, and

59 The women had CD4 lymphocyte counts>400/mm3, no AIDS-defining illness

60 The immediate risk of an ADI for a given CD4 lymphocyte count has declined over time and is lower

61 of plasma HIV RNA level, in addition to the CD4+ lymphocyte count, has a role in guiding the managem

62 Specific studies at baseline should include CD4 lymphocyte count, HIV-1 RNA level, and gynecologic e

63 Despite dramatic increases in CD4(+) lymphocyte counts, IL-2 did not enhance immunizat

64 nsent was obtained for studies that entailed CD4 lymphocyte counts, immunophenotyping, isolator blood

65 Despite higher plasma HIV levels and CD4 lymphocyte counts in infancy, HAART can result in ti

66 NA in plasma, and is a better predictor than CD4+ lymphocyte count in this population.

67 ficiency virus type 1 (HIV-1) RNA levels and CD4+ lymphocyte counts in HIV-infected patients improved

68 NHL incidence rose steadily with decreasing CD4 lymphocyte counts; in contrast, BL incidence was low

69 tained virus suppression, and children whose CD4 lymphocyte counts increased >70 cells/microL by 20 w

70 During antiretroviral therapy, CD4 lymphocyte count increases are modest in some patien

71 points: plasma HIV-1 RNA level (viral load), CD4+ lymphocyte count, initiation of antiretroviral ther

72 odeficiency virus-infected patients when the CD4+ lymphocyte count is < or =200 cells/mm3.

73 The CD4+ lymphocyte count is one such surrogate, but it is r

74 sults were similar in patients with baseline CD4(+) lymphocyte counts less than 0.010 x 10(9) cells/L

75 aths, particularly in those individuals with CD4(+) lymphocyte counts less than 50/mm(3).

76 bed PCP prophylaxis was higher in those with CD4 lymphocyte counts < 250 cells/microL or CD4 cell per

77 Twenty-four patients (55%) had CD4(+) lymphocyte count </= 200/mm(3).

78 Disease progression was defined as CD4(+) lymphocyte count <200/microl or the presence of a

79 progression, comparable with that of cutoff CD4(+) lymphocyte count <350 lymphocytes/mm(3) and HIV-1

80 Cell-mediated immunodeficiency (CD4(+) lymphocyte count <500 cells/mm(3)) was significan

81 increased among HIV-seropositive women with CD4(+) lymphocyte counts <500 cells/mm(3) and among wome

82 Weibull proportional hazards model, baseline CD4+ lymphocyte count <200, black race, other nonwhite r

83 isolated from 10 HIV-infected patients with CD4+ lymphocyte counts < 200/mm3 without signs of active

84 rval, 1.14 to 3.16; P = 0.01), low antenatal CD4+ lymphocyte count (<29 percent of total lymphocytes)

85 vealed an inverse association between IE and CD4 lymphocyte count (odds ratio [OR] for 200-499 cells/

86 No patient without weight loss and a CD4 lymphocyte count of > 100/mm3 had a diagnosis establ

87 II and HIV RNA was measured in serum and the CD4 lymphocyte count of 25 HIV-infected patients was det

88 Five HIV-infected patients with baseline CD4 lymphocyte counts of less than 50 cells/mL were admi

89 iagnosed, all five patients had had absolute CD4 lymphocyte counts of less than 85 cells/microL, and

90 At baseline, patients had a median CD4(+) lymphocyte count of 0.015 x 10(9) cell/L, median

91 Initiating HAART with a CD4+ lymphocyte count of <200 cells/mm3 was associated w

92 o were not using antiviral drugs and who had CD4+ lymphocyte counts of > or = 500 per microliter of b

93 HAART should be initiated at CD4+ lymphocyte counts of >200 cells/mm3.

94 d progressed faster than those with baseline CD4+ lymphocyte counts of >350 cells/mm3 (P=.01).

95 durable virologic suppression with baseline CD4+ lymphocyte counts of >350 cells/mm3 (P=.40).

96 ollers (VCs) (<5,000 HIV-1 RNA copies/ml and CD4+ lymphocyte counts of >400 cells/mul) capable of sol

97 f CMV infected persons with AIDS with either CD4+ lymphocyte counts of < or = 50 per cubic millimeter

98 women was 52.2% when their male partners had CD4+ lymphocyte counts of <200 cells/microL, 45.9% in wo

99 e virologic suppression, those with baseline CD4+ lymphocyte counts of <200 cells/mm3 tended to progr

100 to progress faster than those with baseline CD4+ lymphocyte counts of 201-350 cells/mm3 (P=.09) and

101 ease progression between those with baseline CD4+ lymphocyte counts of 201-350 cells/mm3 and those wi

102 esented with advanced extranodal disease and CD4+ lymphocyte counts of less than 200/mm3.

103 t indicated the need to change the threshold CD4 lymphocyte counts or HIV-RNA levels for initiation o

104 and cord-maternal ratios were independent of CD4(+) lymphocyte counts or HIV-1 viral load.

105 in incidence of HIV-1 infection, virus load, CD4 lymphocyte count, or V3 loop amino acid sequence.

106 duction in HIV-1 RNA level or an increase in CD4+ lymphocyte count, or both, was associated with a de

107 nt relation between plasma HIV RNA level and CD4+ lymphocyte count over time and clinical outcome sug

108 Plasma HIV RNA levels or CD4+ lymphocyte counts over time were more strongly asso

109 Multivariable analysis revealed low CD4 lymphocyte count (p < 0.0001), use of prophylaxis (p

110 irologic outcome (P < 0.001) and increase in CD4 lymphocyte count (P = 0.006).

111 Shortened survival was associated with low CD4 lymphocyte count (P<.0001), no ART (P<.0001), and cr

112 interval, 0.0-4.5%) among those with higher CD4 lymphocyte counts (p < 0.01).

113 n to AIDS correlated strongly with base-line CD4+ lymphocyte counts (P = 0.001) and plasma levels of

114 CD4+ lymphocyte counts, plasma HIV-1 RNA levels, and inf

115 ncorporating both HIV-1 RNA measurements and CD4+ lymphocyte counts provided better discrimination of

116 relationship between level of infection and CD4 lymphocyte count (R = -0.73; P < 0.001).

117 p24 antigen level correlated with both CD4(+) lymphocyte count (r=-0.34; P<.0001) and HIV-1 RNA

118 nonpregnant women according to age, baseline CD4(+) lymphocyte count, receipt of HAART, and date of c

119 optosis are associated with the magnitude of CD4 lymphocyte count recovery during antiretroviral ther

120 oximately 7 months, although those with high CD4 lymphocyte counts seem to do somewhat better.

121 cardiovascular risk factors, HIV viral load, CD4 lymphocyte count, statin use, antihypertensive use,

122 in the incidence of ADIs overall and within CD4 lymphocyte count strata, the relationship with treat

123 n patients not on this treatment within each CD4 lymphocyte count strata.

124 hanges in the plasma HIV-1 RNA level and the CD4+ lymphocyte count, taken together, are valid predict

125 ents who died had significantly lower median CD4 lymphocyte counts than did HIV-seropositive patients

126 Nevertheless, plasma RNA and CD4 lymphocyte count together possess strong clinical pr

127 The pre-ART viral load and CD4+ lymphocyte count trajectories were also comparable

128 national Prognostic Index scores; the median CD4 lymphocyte count was 112/mm(3) (range, 19/mm(3) to 7

129 antiretroviral therapy (ART), and the median CD4 lymphocyte count was 131 cells/microL.

130 The median CD4 lymphocyte count was 19 cells/microliter.

131 The median CD4 lymphocyte count was highest with pathogen-free diar

132 The decline in CD4 lymphocyte counts was strongly associated with initi

133 The median entry CD4(+) lymphocyte count was 20 cells/mm(3) (range, 0 to

134 The median CD4+ lymphocyte count was 13/microL (range, 0 to 200); 7

135 f developing CMV disease (P < 0.001) whereas CD4+ lymphocyte count was not a useful predictor (P = 0.

136 immunodeficiency virus (HIV) infection whose CD4 lymphocyte counts were between 200 and 500 cells/mm3

137 HIV-1 infection and low CD4(+) lymphocyte count were strongly associated with HP

138 >10(6) copies/mL), and both baseline RNA and CD4+ lymphocyte count were independently predictive of s

139 om 1988 through 1998, the viral load and the CD4+ lymphocyte count were measured approximately every

140 Mean (SD) baseline and nadir CD4+ lymphocyte counts were 553(217) and 177(117) cells/

141 CD4+ lymphocyte counts were higher (P < 0.001) and plasm

142 Throughout the 100 weeks, CD4+ lymphocyte counts were higher in the OZ1 group.

143 ve men whose age, body-mass index (BMI), and CD4-lymphocyte count were within the range of values in

144 are based on the viral load, rather than the CD4+ lymphocyte count, will lead to differences in eligi

145 rends toward progressive modest increases in CD4+ lymphocyte counts with GM-CSF treatment at 16 weeks

146 ADIs was seen after stratification by latest CD4 lymphocyte count within each year (< or = 50, 51-200